Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1176 | Clinical Cases–Pituitary/Adrenal | ECE2015

Ectopic ACTH-secreting pituitary adenomas located in the sphenoid sinus: an overview

Johnston Philip C , Kennedy Laurence , Weil Robert J , Hamrahian Amir

Background: Ectopic pituitary adenomas are defined by the presence of adenomatous pituitary tissue outside the sella and distinctly separate from the pituitary gland. Ectopic ACTH-secreting pituitary adenomas (EAPAs) are a rare cause of Cushing’s syndrome. Detecting these radiologically can prove difficult, in part, due to their typically small size and unpredictable anatomical location.Aim: We reviewed the current literature on all previously repor...

ea0037ep1177 | Clinical Cases–Pituitary/Adrenal | ECE2015

Cushing's disease and co-existing phaeochromocytoma

Johnston Philip C , Recinos Pablo , Kennedy Laurence , Hamrahian Amir

Clinical presentation: We report a 46 year old female who presented with a 1 year history of bruising, thin skin and weight gain. In addition; she reported flushing of her chest, heat intolerance, palpitations and abdominal pain. On clinical examination she appeared cushingoid, blood pressure was elevated at 160/98 mm/Hg.Investigations: Biochemical investigations indicated ACTH-dependent Cushing syndrome: 24 h UFC 300 μg (0–50), ACTH 119 pg/ml ...

ea0037gp.22.02 | Pituitary–Therapy of Cushing's disease | ECE2015

Surgical outcome and factors associated with Cushing's disease recurrence in 101 consecutive patients operated on by a single pituitary neurosurgeon: the Cleveland Clinic experience

Johnston Philip C , Hamrahian Amir H , Bena Jim , Weil Bob , Kennedy Laurence

Background: Transsphenoidal tumour resection (TSS) is the first-line treatment for Cushing’s disease (CD). With an experienced neurosurgeon, immediate remission rates >80% are expected for patients with microadenomas (<10 mm).Aim: To report initial and long-term remission rates in a specialist centre, and to ascertain factors associated with disease recurrence after TSS.Methods: Patients with CD (n=101, 28M, 7...

ea0037ep748 | Pituitary: clinical | ECE2015

Body weight changes in patients with active Cushing disease after transsphenoidal surgery

Johnston Philip C , Hamrahian Amir H , Weil Robert J , Kennedy Laurence

Background: Successful pituitary surgery in patients with Cushing disease (CD) can result in long term remission and sustained weight loss. We examined rates of body weight changes in the post-operative period (within 6 months) in patients with active CD who underwent transsphenoidal surgery (TSS) and the relationship of weight loss to remission status.Methods: Clinical data was obtained from a CD database in addition to an online patient medical record ...

ea0037ep779 | Pituitary: clinical | ECE2015

The impact of surgical management of Cushing's disease in pregnancy on foetal outcomes

Johnston Philip C , Abbassy Mahmoud , Hamrahian Amir , Kennedy Laurence , Recinos Pablo

Background: Cushing’s disease is a condition rarely encountered during pregnancy. It is known that hypercortisolism is associated with increased maternal and foetal morbidity and mortality.Aims and methods: A comprehensive search of the literature was performed for cases of Cushing’s disease in pregnancy including our own case. Analysis was performed of all pregnant patients with Cushing’s disease who were treated with surgery compared to ...

ea0037ep1178 | Clinical Cases–Pituitary/Adrenal | ECE2015

Cushing's disease from an ectopic parasellar adenoma

Johnston Philip C , Kennedy Laurence , Hamrahian Amir H , Weil Robert J

Background: Most cases of Cushing’s disease originate from the pituitary, rarely the source of excess ACTH is from an ectopic pituitary adenoma.Case: A 34-year-old woman had a 12-month history of a labile mood, weight gain, easy bruising, irregular menses and hypertension, she appeared cushingoid. Biochemical investigations demonstrated hypercortisolism: 24 h urine-free cortisol 520.7 μg (4–50), ACTH 152 pg/ml (8–42); midnight salivar...

ea0035oc8.4 | Pituitary clinical | ECE2014

Normalization of urinary cortisol with the potent 11β-hydroxylase inhibitor LCI699 in patients with Cushing's disease: 22-week, multicentre, open-label study

Biller Beverly , Young Jacques , Hamrahian Amir , Fleseriu Maria , Molitch Mark , Pivonello Rosario , Shimatsu Akira , Shimizu Chikara , Tanaka Tomoaki , White Tracy , Hilliard Annie , Tian Chuan , Sauter Nicholas , Bertagna Xavier

Background: A proof-of-concept study (LINC 1) demonstrated that after 10 weeks, LCI699 normalized UFC in 11/12 patients with Cushing’s disease. This interim analysis of the first eight patients enrolled into a longer-term study (LINC 2) further evaluates LCI699 in Cushing’s disease; the full analysis on all 19 enrolled patients is expected in time for the congress.Methods: There were two study groups. Previous LINC 1 participants (follow-up coh...

ea0090ep801 | Pituitary and Neuroendocrinology | ECE2023

An Open-Label Extension Study to Evaluate the Safety of Long-term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

Badiu Corin , Mariash Cary N. , Kautzky-Willer Alexandra , Shlomai Gadi , Aresta Carmen , Pivonello Rosario , Dischinger Ulrich , Bancos Irina , Dobri Georgiana , Hamrahian Amir , Auchus Richard , Feelders Richard , Recasens Monica , Chmiel-Perzynska Iwona , Pearson Emily , Moraitis Andreas G. , Araque Katherine

Cushing syndrome (CS) is a chronic and debilitating condition with high morbidity and mortality. Development of novel, safe, and effective pharmacologic therapies with improved risk-benefit profiles would enrich treatment options for patients. Relacorilant is a selective glucocorticoid receptor (GR) modulator that competitively antagonizes cortisol activity and, unlike the FDA-approved GR antagonist mifepristone, does not bind to the progesterone receptor. In a phase 2 study i...